Clinical Trial Search

Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants

Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants

Primary: Overall Response Rate — 3 Participants

Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243

Primary: Objective Response Rate (ORR) — 35.2; 51.9 Percentage of participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection — 16 Participants

Primary: Cure Rate — 751 lesions

Primary: Overall Response Rate in Participants With c-Met Positive Lung Squamous Cell Carcinoma (SCCA) — 9 percentage of participants

Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants

Primary: Early Progression Rate — 31.8 percentage of participants

Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants

Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005

Primary: Incidence of Treatment Emergent Adverse Events — 4; 3; 5; 10 Participants

Primary: Overall Response Rate (ORR) by Independent Central Review — 50.8; 44.9; 46.4; 61.9 percentage of participants

Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 0 percentage of patients

Primary: Progression-free Survival — 11.2 months

Primary: Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates — 6.81; 18.18; 75.00 percentage of participants

Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects

Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy

Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants

Primary: Progression Free Survival (PFS) of All Participants — 6; 36 weeks

Primary: Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period — 29; 62 percentage of participants

Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Overall Response Rate — 22.7 percentage